WHO grants Sinopharm’s COVID-19 vaccine emergency approval

Sinopharm’s vaccine, the first Chinese candidate, is an inactivated two-dose schedule vaccine, with ‘easy’ storage requirements that make it suitable for low-resource settings. Vaccine efficacy for symptomatic and hospitalised disease was estimated to be 79%, for all age groups

Source:

World Health Organization